Type 1 Diabetes Clinical Trial
Official title:
Repeatability of Blood Glucose Responses to Fasted and Fed Resistance Exercise in Individuals With Type 1 Diabetes
Verified date | January 2024 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study proposes to examine the impact of time of day (morning versus afternoon) on the variability of blood glucose responses to high resistance exercise in a single group of patients with type 1 diabetes. Participants will be asked to wear a continuous glucose monitor during the 3 weeks of testing. During the six exercise sessions (three in the morning while fasted and three in the afternoon), participants will complete the same resistance exercise protocol.
Status | Completed |
Enrollment | 27 |
Est. completion date | December 16, 2023 |
Est. primary completion date | December 16, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - type 1 diabetes diagnosed for at least 1 year - aged 18 to 55 years Exclusion Criteria: - HbA1c > 9.9% - frequent and unpredictable hypoglycemia - change in insulin management strategy within two months of study - using closed-loop insulin delivery - injuries that would contraindicate resistance exercise - blood pressure > 140/95 - severe peripheral neuropathy - a history of cardiovascular disease - severe proliferative retinopathy |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Diabetes Institute | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | DexCom, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Capillary glucose (change during exercise) | Using test strips and a hand-held glucometer to test blood from a finger poke | 0 minutes (exercise start), 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes | |
Secondary | Mean CGM glucose | mean CGM glucose | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | CGM coefficient of variation (CV) | coefficient of variation of continuous glucose monitoring data | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | CGM standard deviation (SD) | Standard deviation of CGM glucose | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | frequency of hypoglycemia | number of hypoglycemic events measured by CGM | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | frequency of hyperglycemia | number of hyperglycemic events measured by CGM | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | percent time in range | percent of time spent between 4.0 and 9.9 mmol/L | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | percent time in hyperglycemia | percent of time spent over 10.0 mmol/L | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise | |
Secondary | percent time in hypoglycemia | percent of time spent below 3.9 mmol/L | 6 hours, 12 hours, overnight (midnight to 6am) and 24 hours post-exercise |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|